By Reuters | PARIS |
Topics Sanofi | Sanofi India | Coronavirus
PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.
Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world. This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza.....
This article is no longer available in our repository.
There could be multiple reasons for this.
You could try searching for this headline on the source website (bloomberg.com).